The LOTUS trial is a Phase 2 clinical study evaluating LY-3372689 (zaniglusemab), an oral O-GlcNAcase (OGA) inhibitor developed by Eli Lilly, in patients with progressive supranuclear palsy (PSP). This is the first OGA inhibitor trial beyond PROSPER to evaluate this mechanism in a pure 4R-tauopathy[1].
LOTUS provides an important competitive benchmark for FNP-223/PROSPER and tests whether OGA inhibition can show clearer benefit in PSP (a pure tauopathy without amyloid comorbidity) compared to AD where MAGNOLIA did not meet its cognitive endpoint. The trial represents a critical test of the hypothesis that pure tauopathies may respond better to tau-directed therapies than Alzheimer's disease where amyloid co-pathology complicates interpretation[2].
| Parameter | Value |
|---|---|
| Trial ID | NCT05682807 |
| Phase | Phase 2 |
| Status | Active, not recruiting |
| Drug | LY-3372689 (zaniglusemab) |
| Company | Eli Lilly |
| Indication | Progressive Supranuclear Palsy (PSP) |
| Enrollment | ~100 patients |
| Duration | 52 weeks treatment |
| Primary Endpoint | PSPRS change from baseline |
| Secondary Endpoints | Safety, CSF biomarkers, cognitive measures |
| Start Date | 2023 |
| Completion | Q4 2026 |
Tau protein is a microtubule-associated protein that plays crucial roles in neuronal axonal transport and cytoskeletal stability. In neurodegenerative diseases, tau becomes hyperphosphorylated, leading to aggregation into neurofibrillary tangles (NFTs), which are a hallmark of multiple disorders including AD, PSP, and CBD[3].
O-GlcNAcylation is a post-translational modification where N-acetylglucosamine (GlcNAc) is covalently attached to serine and threonine residues on proteins. This modification is distinct from N-linked or O-linked glycosylation and serves as a dynamic regulatory mechanism akin to phosphorylation:
The balance between O-GlcNAcylation and phosphorylation on tau is dynamically regulated by two enzymes:
The LOTUS trial in PSP was strategically important for several reasons[4][5]:
| Aspect | LOTUS (LY-3372689) | PROSPER (FNP-223) |
|---|---|---|
| Drug | Zaniglusemab | FNP-223 |
| Company | Eli Lilly | Ferrer |
| Enrollment | ~100 patients | 241 patients |
| Design | Dose-finding | Dose-finding |
| Endpoint | PSPRS | PSPRS |
| Results Expected | Q4 2026 | Q4 2026/Q1 2027 |
| Route | Oral | Oral |
If LOTUS shows clearer benefit than MAGNOLIA (AD), it would support the hypothesis that:
Primary:
Secondary:
Exploratory:
LY-3372689 inhibits O-GlcNAcase (OGA), the enzyme that removes O-GlcNAc modifications from proteins including tau. By inhibiting OGA, the drug increases cellular levels of O-GlcNAcylated proteins[2:1]:
The mechanistic hypothesis is supported by preclinical data showing:
The mechanistic pathway can be visualized as:
| Biomarker | Interpretation |
|---|---|
| Elevated CSF O-GlcNAc | Successful target engagement |
| Reduced p-tau181 | Decreased tau pathology |
| Stable NfL | Neuroprotection |
| Slower brain atrophy | Disease modification |
The LOTUS trial addresses key learnings from the MAGNOLIA trial in AD:
The OGA inhibitor landscape shows multiple companies pursuing this mechanism:
| Trial | Drug | Company | Indication | Status |
|---|---|---|---|---|
| LOTUS | LY-3372689 | Eli Lilly | PSP | Active |
| PROSPER | FNP-223 | Ferrer | PSP | Active |
| MAGNOLIA | LY-3372689 | Eli Lilly | AD | Completed |
| Approach | Mechanism | Examples |
|---|---|---|
| Anti-tau antibodies | Passive immunization | Semorinemab, Tilavonemab, Bepranemab |
| Tau aggregation inhibitors | Small molecule | Methylene blue derivatives |
| OGA inhibitors | Enhance O-GlcNAc | LY-3372689, FNP-223 |
| Kinase inhibitors | Reduce phosphorylation | GSK-3β inhibitors |
| Tau degradation | Autophagy/UPS | Autophagy modulators |
The LOTUS trial is actively following patients with completion expected in Q4 2026. Results will be announced around the same time as PROSPER (FNP-223), enabling direct comparison of two OGA inhibitors in PSP.
Key Milestones:
Yuzwa SA, et al. O-GlcNAc elevation in Alzheimer's disease. Nature Neuroscience. 2016. ↩︎ ↩︎
Jacobson DH, et al. Tau O-GlcNAcylation and phosphorylation in disease. Cellular and Molecular Neurobiology. 2020. ↩︎
West M, et al. OGA inhibition reduces tau pathology in models. Journal of Biological Chemistry. 2019. ↩︎
Morizawa Y, et al. OGA inhibitor development for tauopathies. Journal of Medicinal Chemistry. 2022. ↩︎